Outbreak of highly resistant A. baumannii in Wisconsin care facilities: an in-depth genetic characterization
Kelsey Florek, MPH, PhD
2019 AMD 2-Day
September 23, 2019
Slides live from: www.k-florek.net/talks
Overview
Inital Case
Outbreak Investigation
Genetic Characterization
September 2018
Patient at facility A with a lower respiratory infection 3 months after a heart transplant
Respiratory cultures revealed a carbapenem resistant A. baumannii
Treatment:
Polymixin-B
Meropenem
Colistin
Cefiderocol as compassionate treatment
Patient passed away, unclear if cause was sepsis
5 additional patients from Facility A had sputum cultures that were positive for carbapenem resistant A. baumannii
Wisconsin State Laboratory of Hygiene
Determining relatedness
Antimicrobial susceptibility
Amikacin: Resistant
Aztreonam: Resistant
Cefepime: Resistant
Cefotaxime: Resistant
Ceftazidime: Resistant
Ciprofloxacin: Resistant
Colistin: Susceptible
Doripenem: Resistant
Doxycycline: Resistant
Gentamicin: Resistant
Imipenem: Resistant
Levofloxacin: Resistant
Meropenem: Resistant
Minocycline: Intermediate
Piperacillin-tazobactam: Resistant
Polymyxin-B: Susceptible
Ticarcillin-clavulanate: Resistant
Tobramycin: Resistant
Trimethoprim-sulfamethoxazole: Resistant
Outbreak isolates are OXA-72
Case Definitions
Probable
Carbapenem resistant A. baumannii clinical isolate with outbreak AST profile
Confirmed
Carbapenem resistant A. baumannii clinical isolate genetically clustering with other outbreak isolates and harboring the OXA-24/40-like β-lactamase OXA-72
Case Definitions
Probable (n=43)
Carbapenem resistant A. baumannii clinical isolate with outbreak AST profile
Confirmed (n=22)
Carbapenem resistant A. baumannii clinical isolate genetically clustering with other outbreak isolates and harboring the OXA-24/40-like β-lactamase OXA-72